Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Circadacare is a health technology company focused on enhancing the quality of life for older adults in care environments. By leveraging scientific principles, the company offers innovative lighting solutions that synchronize with the natural day-night cycle, improving the well-being of residents while also benefiting staff. Their integrated system combines lighting, sensors, and software technology to create an optimal care setting that fosters mood and engagement. Circadacare aims to simplify operations for care providers, ensuring that their systems function seamlessly without requiring extensive training or intervention from staff. This approach not only enhances care outcomes for residents but also offers cost benefits to operators of nursing homes, care villages, and dementia care centers.

EnrichMyCare is a technology company that specializes in developing a personal health platform. This platform aims to centralize and streamline care coordination for children, improving communication between families and various healthcare, social care, and education providers. It enables instant sharing of records and remote monitoring of the child's welfare, simplifying the complex process of managing care. The platform also offers features to automate care pathways, monitor management plans, and ensure compliance with exercise and splinting programs. The ultimate goal is to accelerate care, enhance patient monitoring and engagement, prevent disabilities, and improve the overall care experience while reducing healthcare costs.

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Axial3D specializes in 3D printing for healthcare, focusing on creating precise, patient-specific physical models derived from CT and MRI scans. Their online ordering portal enables secure uploads, with an expert team using advanced technology to deliver these models directly to consultants. The company aims to enhance surgical planning, technique development, and ultimately improve patient outcomes by integrating 3D printing into mainstream medical practice.

MediMusic is a developer of a medical technology platform that harnesses the power of soothing music to assist patients in managing pain, anxiety, and stress. The company employs artificial intelligence to curate personalized playlists that not only lower heart rates but also stimulate the vagus nerve, promoting a favorable physio-endocrine response. This innovative approach aims to help individuals reduce stress and anxiety while enhancing the efficacy of pain medication, thereby contributing to overall well-being. MediMusic focuses on improving patient care through its unique blend of health technology and music therapy, targeting conditions such as dementia and anxiety.

LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.

The goal of Reneural is to use technology to revolutionize healthcare delivery by increasing its effectiveness, efficiency, and accessibility for both patients and physicians.

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Myogenes provides psychiatric tests, heredity cancer tests, and mental health mind maps.

Kaydiar is a medical device company focused on developing innovative offloading technologies for pressure injuries. Their product range includes orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves, all designed to reduce pressure on damaged skin or tissue, promoting cost-effective wound care.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lentitek is a cell and gene therapy company focused on developing innovative treatments for cancer patients. The company is dedicated to making advanced therapeutics more accessible by enhancing the production of lentiviral vectors, which are essential for gene therapies. Lentitek employs a proprietary method that utilizes a novel promoter and a triple transfection production process to significantly increase viral yields by tenfold or more. This approach not only improves the efficiency of lentiviral production but also aims to lower production costs for healthcare providers, thereby broadening the availability of its therapies to a larger patient population.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Naitive is a population health company focused on transforming patient care through the development of AI-enabled clinical pathways. It specializes in creating medical device technology aimed at preventing chronic diseases. The company's software leverages artificial intelligence, clinical data, and digital interventions to enhance the detection, treatment, and management of chronic conditions. By utilizing scalable computational capabilities, Naitive's solutions enable clinicians to improve care coordination while reducing costs, time, and the likelihood of treatment failures.

Siloton is a medical device manufacturing company specializing in the design and development of diagnostic imaging devices for ophthalmology. The company focuses on creating portable optical coherence tomography devices aimed at addressing challenges within this field. Notably, Siloton develops advanced hand-held sub-surface imaging devices that enable clients to use a home-based scanning module, contributing to the prevention of blindness.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

KYMIRA is an e-commerce company specializing in smart garments and textiles designed to enhance athletic performance and recovery. The company develops innovative textiles that incorporate compression fabric, infrared technology, and sensors, which harness and recycle the energy of athletes. These products aim to improve performance, address chronic health issues, reduce injury risks, and enhance sleep quality. By providing data insights, KYMIRA enables athletes and sports enthusiasts to optimize their training and recovery processes.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

SleepCogni is a company focused on developing innovative sleep aid technology aimed at enhancing the sleep experience for users. It offers a unique wind-down process that incorporates cognitive behavioral therapy and biofeedback. The company's device utilizes sensors worn on the user's index finger to monitor various physiological and behavioral metrics, including heart rate, mental alertness, skin temperature, and movement. By analyzing this data, SleepCogni provides personalized biofeedback through visual, auditory, and tactile cues, helping users effectively relearn the process of falling asleep. Ultimately, SleepCogni's technology seeks to assist individuals in overcoming insomnia and improving their overall sleep cycle.

machineMD is a Switzerland-based medical device company with a subsidiary in Boston, USA, focused on advancing diagnostic capabilities in neuroscience and ophthalmology. The company aims to enhance the measurement of brain function, striving for rapid and accurate diagnoses of brain disorders. machineMD has developed an automated medical device that replaces traditional manual assessments of eye movements and pupillary function, which are often time-consuming and subjective. This innovation allows medical assistants to conduct fast, objective, and standardized examinations, providing ophthalmologists and neurologists with reliable measurements essential for effective diagnosis and treatment. By collaborating with a global network of clinical and research partners, machineMD seeks to extend the diagnostic quality of specialized care to primary and secondary healthcare settings, improving patient outcomes in the process.

GaitQ Limited is a medical device company founded in 2019 and based in Oxfordshire, United Kingdom. It specializes in developing the GaitThaw device, which addresses the issue of gait freezing in individuals with Parkinson's disease. This small and portable device employs clinically proven sensory cues to assist patients in re-establishing the connection between the brain and body, thereby facilitating smoother walking. GaitQ aims to improve mobility and enhance the quality of life for those affected by this debilitating symptom of Parkinson's disease.

Graphene Trace is a healthcare technology company that specializes in preventing pressure ulcers, a common issue among wheelchair users and hospital patients. The company's core product is a smart, pressure-sensing fabric that continuously monitors pressure distribution, alerting users and caregivers in real-time to repositioning needs. This innovative solution enables early intervention, preventing pressure ulcers, and ensuring user comfort and affordability.

Renude is a company that offers personalized skincare advice through its artificial intelligence platform. It aims to make reliable and individualized skin consultations accessible to a global audience. The team at Renude comprises dermatologists, formulation chemists, licensed aestheticians, data scientists, and machine learning engineers who collaborate to develop dermatologist-approved AI skin advisors. These advisors facilitate virtual consultations with licensed aestheticians, who craft tailored skincare plans based on users' specific goals, needs, preferences, budget, and lifestyle. Through its innovative approach, Renude seeks to empower individuals to achieve their skincare objectives effectively.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

Lucida Medical is a healthcare technology company focused on developing artificial intelligence solutions to enhance the detection and diagnosis of cancer. The company’s flagship product, Pi, is a CE marked medical device that utilizes multiparametric and diffusion MRI to support prostate cancer diagnosis. By leveraging advanced imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with accurate, accessible, and cost-effective tools for cancer screening and management. Their innovative technology is designed to improve the efficiency of cancer detection, ultimately enabling healthcare professionals to make timely and informed decisions regarding patient care.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Holly Health is a digital health application designed to assist individuals in translating their health intentions into actionable daily practices for improved mental and physical wellbeing. Utilizing proprietary AI technology, the platform provides a personalized and empathetic experience that simulates the guidance of a human health coach. The application has received high ratings for its effectiveness in weight management, stress reduction, wellness, and sleep, earning a commendable score of 89% from ORCHA, a leading health app evaluation organization. Since its international launch in Summer 2021, Holly Health aims to support 5 million users by 2025 and is expanding its presence through partnerships with primary care practices in the UK, having established over 100 collaborations to date. The app features habit reminders, tailored health content, progress tracking, and motivational support, enabling users to prioritize and maintain healthier habits in their daily lives.

At Holly Health, we are transforming the way individuals approach mental and physical well-being. Founded in 2020, we’ve developed an AI-powered digital health coach that empowers users to turn their health intentions into clear, actionable steps. Our personalized, compassionate service is designed to fit seamlessly into everyday life, supporting long-term, sustainable health changes. Using proprietary AI systems, Holly Health mimics the guidance of a human health coach, offering support in areas such as weight management, stress reduction, wellness, and sleep. We are proud to be ranked among the top 3 health apps by ORCHA, the world’s leading health app evaluation body, with a score of 89%. Since our international launch in 2021, Holly Health has been on a mission to improve the lives of 5 million people by 2025. We are rolling out partnerships with over 100 primary care practices in the UK, helping healthcare professionals support patients with preventative health measures and ongoing well-being. At Holly Health, we believe that health is not a destination but a journey. By offering tailored, science-backed coaching, we make it easier for people to prioritize their well-being every day. Join us as we revolutionize digital health coaching for the modern world.

Holly Health is a digital health application designed to assist individuals in translating their health intentions into actionable daily practices for improved mental and physical wellbeing. Utilizing proprietary AI technology, the platform provides a personalized and empathetic experience that simulates the guidance of a human health coach. The application has received high ratings for its effectiveness in weight management, stress reduction, wellness, and sleep, earning a commendable score of 89% from ORCHA, a leading health app evaluation organization. Since its international launch in Summer 2021, Holly Health aims to support 5 million users by 2025 and is expanding its presence through partnerships with primary care practices in the UK, having established over 100 collaborations to date. The app features habit reminders, tailored health content, progress tracking, and motivational support, enabling users to prioritize and maintain healthier habits in their daily lives.

CellRev is a biotechnology company that specializes in advancing cell manufacturing processes through innovative bioprocessing technology. The company focuses on enabling the transition from traditional batch processing to continuous processing for adherent cells, which enhances yield and reduces both operating costs and capital expenditure. By addressing critical challenges such as aggregation, clumping, and cell detachment, CellRev offers unique solutions for developers in the fields of cultured meat, cell therapy, and biologics. Its proprietary cell detachment process, combined with a specially designed bioprocess, positions CellRev as a leader in improving the efficiency of manufacturing processes for cell-based vaccines, therapies, and drugs. This disruptive approach aims to eliminate the need for serum in production, thereby streamlining operations for clients in the biomanufacturing landscape.

Bioliberty is a medtech startup focused on developing innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company specializes in creating robotic gloves that leverage artificial intelligence to aid muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These solutions are designed to address hand weakness, empowering users to perform daily tasks and enhance their hand strength, ultimately enabling them to live more comfortably and independently in their own homes.

BelleVie is a provider of personal care services designed to support individuals in their daily lives while allowing them to maintain their independence. The company offers a range of services, including personal care, meal preparation, home assistance, social engagement, and specialized care. Its operating model is inspired by the Buurtzorg approach, emphasizing self-managing teams that foster meaningful relationships within the care ecosystem. BelleVie aims to create a society where every individual is valued and supported, promoting fulfilling careers within the care sector. To enhance its operations, the company utilizes a custom Wellbeing OS technology platform, which is underpinned by a subscription-based funding model.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Spirecut is a MedTech company that specializes in developing patented surgical instruments for treating hand conditions, specifically carpal tunnel syndrome and trigger finger. The company's innovative approach utilizes ultrasound-guided surgery, eliminating the need for skin incisions and resulting in no post-operative wounds. This advancement allows patients to resume their daily activities without the necessity of dressing or covering the operated area. Spirecut's instruments represent a significant improvement over traditional needles, facilitating the safe release of thickened tissue and enhancing preoperative sonographic tracking. By optimizing surgical outcomes, Spirecut aims to elevate the standard of care in hand surgery and accelerate patient recovery.

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

Jude is a healthcare company focused on addressing bladder-related issues and raising awareness about incontinence. It provides a range of bladder care solutions, including access to medical specialists who offer advice through social media platforms, virtual workshops, and private chat sessions. In addition to educational resources, Jude supplies health products designed to help individuals understand their conditions and manage them effectively. By promoting open discussions and providing expert guidance, Jude aims to empower individuals to lead leak-free lives and break the stigma surrounding bladder health.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

NK:IO is a biotechnology company focused on advancing innovative strategies for natural killer cell-mediated immunotherapy. It specializes in the development of both cell therapies and small molecule therapeutics, with a primary emphasis on cancer treatment. By harnessing the capabilities of natural killer cells, NK:IO aims to enhance the effectiveness of cancer therapies, providing physicians with improved tools to combat the disease. The company's commitment to research and development positions it at the forefront of immunotherapy advancements in the oncology field.

Corryn Biotechnologies is a biotechnology company focused on innovative solutions for chronic wound care. The company has developed the Heals device, which utilizes a contactless approach to enhance the dressing of chronic and complex wounds. Corryn's technology employs applicators that use voltages to extrude fine fibers from various fluids, allowing for the creation of advanced wound dressings. These dressings can be made from both synthetic and natural materials, with the option to include active ingredients. This method enables the deposition of non-woven meshes, contributing to effective tissue repair and improving patient outcomes in wound management.

Damibu Ltd is a technology company specialising in innovative digital solutions, particularly for healthcare and public sector organisations. They focus on creating platforms that simplify content management and distribution, enhancing communication efficiency. Notably, their product Damibu Feeds aids NHS groups in the UK by automating content sharing among GP surgeries, saving time and resources. Their approach emphasises user-friendly designs and interoperability, ensuring seamless integration with existing systems. Damibu's commitment to improving digital health communication is evident in their solutions, which aim to streamline processes, ensure content accuracy, and enhance patient engagement through reliable and accessible information dissemination.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

Autolomous Ltd is a technology company founded in 2019 and based in Mayfair, United Kingdom, that specializes in developing software solutions for cell and gene therapy manufacturers. Its flagship platform, autoloMATE®, is a cloud-native system that offers comprehensive, end-to-end solutions for advanced therapy manufacturing. The platform facilitates the scheduling of patient cell collections, transportation logistics, and tracking of the manufacturing process to ensure compliance with regulatory requirements. Additionally, autoloMATE® supports the management of electronic batch records, provides insights reporting, and oversees review and release activities. The software is designed to be highly configurable, allowing clients to customize workflows to suit their needs. Autolomous emphasizes compliance with regulatory standards and has achieved multiple ISO certifications in areas such as information security, quality management, and environmental management. By leveraging advanced technology and secure data management practices, Autolomous aims to enhance the availability and affordability of autologous medicines for patients.

Change My Face is an AI-powered face-changing technology used in healthcare, finance and skincare.

CalmBrain is a digital platform that provides psychological intervention for schools to assist students in managing their mental health, including anxiety, stress, and trauma.

Kids Speech Labs is a digital health company focused on transforming the delivery of speech and language therapy services through innovative technology. The company utilizes artificial intelligence to create engaging speech and language games, which facilitate remote monitoring of children's speech development. This approach allows parents to actively track their children's progress in a more interactive and effective manner. By leveraging AI-driven solutions, Kids Speech Labs aims to enhance the accessibility and effectiveness of speech therapy, ultimately supporting better outcomes for children in need of these services.

Mumbli is a company focused on enhancing hearing experiences through the integration of technology and personal hearing solutions. It develops a hearing wellness platform that employs wireless sound sensors to monitor and optimize acoustic environments. By certifying venues based on conversation quality and healthy noise levels, Mumbli ensures accessibility for individuals who are hard of hearing or sensitive to noise. Its IoT system provides real-time data on sound performance, enabling venue staff to make informed decisions regarding sound management and addressing customer concerns effectively.

Boost Innovations is a company focused on developing products specifically for women, with a particular emphasis on breast prostheses. Its primary offering is a specialized breast form designed to enhance comfort and usability for individuals who have undergone surgery. The prosthesis is engineered to remain securely in place when worn with post-surgery underwear, and it is suitable for various activities, including swimming and exercising. By prioritizing breathability and functionality, Boost Innovations aims to boost the confidence of its users and cater to their unique needs.

Juniver is a company focused on supporting individuals in long-term recovery from eating disorders through a neuroscience-based recovery program. It offers a platform that provides practical tools and habit-formation principles tailored to address disordered eating. By fostering a supportive community, Juniver enables users to manage cravings and ease urges, promoting sustainable recovery. The company's approach emphasizes specialized care and on-demand assistance, creating a comprehensive network for those seeking help in their journey towards healing.

The Allergy Team assists families, companies, and educational institutions in managing food allergies.

Life with Zeal a lifestyle brand that is revolutionizing the assisted living market.

Orthonika Limited, founded in 2014 and based in London, United Kingdom, specializes in the development of anatomical meniscus replacement devices, specifically the MenisciKnit. This innovative product addresses the significant clinical gap in treating meniscus injuries, which can lead to debilitating conditions such as osteoarthritis. Traditional treatment methods, including partial meniscectomy and allograft transplantation, have notable limitations, such as incomplete restoration of knee biomechanics and issues related to donor availability and infection risk. Orthonika's MenisciKnit utilizes a unique fiber-reinforced structure embedded in a proprietary polymer, effectively mimicking the natural tissue's properties. This advanced approach aims to restore knee function, helping patients with severe meniscus injuries return to an active lifestyle while fulfilling a critical unmet need in orthopedic care.

Tycho Medlink is to help people achieve new levels of rehabilitation through digital therapy.

Recreo VR operates a virtual reality (VR) platform that offers VR headsets, curated content, and support services. This platform enables residents, particularly those in care settings, to explore new experiences, revisit cherished memories, and connect with others through immersive VR environments.

Rescape Innovation Limited is a healthcare technology company based in Cardiff, United Kingdom, established in 2017. The company specializes in the design and manufacture of healthcare equipment, focusing on virtual reality distraction therapy. Rescape Innovation's technologies aim to address challenges in the healthcare sector, particularly in reducing anxiety and pain for patients while enhancing their overall experience. By leveraging virtual reality, the company seeks to improve communication and management of stress-related issues in clinical settings.

InsideOut is a London-based company focused on mental health care and well-being support. It has developed a therapy platform aimed at reducing social stigma surrounding mental health and facilitating open conversations about the subject. The platform provides users with continuous therapy support through an online application that employs an intelligent matching system to connect individuals with the appropriate therapist. This approach enhances users' ability to maintain positive mental well-being by ensuring they receive tailored support based on their specific needs.

SyncVR Medical is a leading provider of virtual reality (VR) and augmented reality (AR) solutions for the healthcare sector, operating as the largest XR platform in Europe and the UK. The company offers a comprehensive platform that simplifies the implementation and use of XR technologies across healthcare organizations, supporting over 125 institutions in countries such as the Netherlands, Germany, Denmark, Sweden, Belgium, the UK, and France. SyncVR Medical focuses on enhancing patient care by reducing pain and anxiety, while also improving treatment outcomes through scientifically validated methods. Additionally, the platform facilitates collaboration with more than 25 third-party developers, allowing them to distribute their XR healthcare applications to a broader audience. SyncVR Medical aims to establish itself as the dominant XR platform in the top five European healthcare markets by 2025.

Care Reality are a hybrid of EdTech and HealthTech building a new reality for learning.

XR Therapeutics is a start-up company that emerged from Newcastle University, building on over a decade of academic research. The company operates a healthcare services platform designed to assist individuals suffering from anxiety and phobias through innovative therapies. Its primary offering is a unique virtual reality treatment that integrates traditional Cognitive Behaviour Therapy with immersive virtual environments. This approach allows practitioners to create tailored experiences that address the specific needs of each patient, facilitating effective treatment for both adults and children facing mental health challenges.

Neu Health is a developer of a smartphone-based clinical platform designed to enhance personalized care for patients with Parkinson's disease and dementia. The company's innovative platform leverages artificial intelligence to monitor and interpret digital measures of clinically relevant symptoms. By optimizing condition management, Neu Health aims to reduce the burden on clinicians while improving patient outcomes. This approach enables healthcare providers and caregivers to deliver more efficient and effective care, addressing the challenges associated with managing these complex neurological conditions.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Calla Lily Clinical Care is a B-Corp focused on women's health, specializing in innovative drug delivery systems. It has developed the proprietary Callavid® platform for intravaginal drug administration, aiming to enhance patient outcomes in fertility and pregnancy. The company is working towards launching the first drug-device combination product designed to prevent miscarriages and provide luteal phase support for In Vitro Fertilization (IVF). Additionally, Callavid® is capable of delivering live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic usage and the spread of antimicrobial resistance. The company also offers the Lilyvid™ device for effective medical sample collection, which facilitates advanced biomarker-based diagnostic tests for conditions such as endometriosis. The technology behind Calla Lily's devices has been recognized as a TIME Magazine Best Invention of the Year, reflecting its innovative approach to women's healthcare.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.

Syndi is a digital health support recommendation platform that utilizes machine learning and digital phenotyping, with a primary focus on mental health. The company develops technology-driven solutions aimed at enhancing individuals' health by providing effective and accessible support. Syndi's platform employs passive smartphone data collection to gather moment-to-moment information about users, allowing it to deliver personalized and immediate care. This innovative approach not only facilitates connections between patients and healthcare providers but also measures the effectiveness of applications and digital services in treating invisible disabilities. Through its commitment to leveraging technology and research, Syndi seeks to improve healthcare outcomes for its users.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

PatientMpower specializes in remote monitoring solutions for patients with chronic diseases, particularly those with respiratory conditions. The company develops applications that integrate with devices such as spirometers and pulse oximeters, allowing patients to conduct health measurements from home. These devices connect to a smartphone application, which facilitates the transmission of real-time data to healthcare providers. This integration enhances the ability of healthcare workers to deliver high-quality care and monitor patient progress effectively. Additionally, PatientMpower’s solutions contribute to research efforts aimed at improving treatment methodologies, ultimately supporting better health outcomes for patients.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Fly Mama is an online membership platform dedicated to supporting pre and postpartum well-being for mothers. It provides trauma-informed integrated healthcare solutions that address the mental, emotional, and physical needs of women during and after pregnancy. The platform offers professional support for various challenges, including fertility journeys, perinatal trauma, and loss. By empowering women, Fly Mama aims to enhance their confidence and happiness throughout their motherhood journey. Additionally, the company envisions launching an employee benefit program designed to assist women during and after pregnancy, further emphasizing its commitment to maternal well-being.

KYMIRA is an e-commerce company specializing in smart garments and textiles designed to enhance athletic performance and recovery. The company develops innovative textiles that incorporate compression fabric, infrared technology, and sensors, which harness and recycle the energy of athletes. These products aim to improve performance, address chronic health issues, reduce injury risks, and enhance sleep quality. By providing data insights, KYMIRA enables athletes and sports enthusiasts to optimize their training and recovery processes.

BelleVie is a provider of personal care services designed to support individuals in their daily lives while allowing them to maintain their independence. The company offers a range of services, including personal care, meal preparation, home assistance, social engagement, and specialized care. Its operating model is inspired by the Buurtzorg approach, emphasizing self-managing teams that foster meaningful relationships within the care ecosystem. BelleVie aims to create a society where every individual is valued and supported, promoting fulfilling careers within the care sector. To enhance its operations, the company utilizes a custom Wellbeing OS technology platform, which is underpinned by a subscription-based funding model.

Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

Emm is focused on creating advanced consumer health tools that enable individuals to manage their health according to their personal preferences. The company is developing a wearable device specifically designed to enhance reproductive health by providing biometric data. This data offers actionable insights into an individual's unique reproductive profile, allowing users and their healthcare providers to identify potential health issues and improve overall reproductive health outcomes. Emm aims to empower individuals by fostering a deeper understanding of their health through innovative technology and specialized knowledge.

Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

Ascentys provides digital health business services.

Enhanced Fertility is a digital health company that uses data, artificial intelligence, and remote diagnostics to improve fertility care. It aims to increase access to fertility treatment for the 1 in 6 couples globally facing infertility, with less than 2% currently able to access needed care. The company's platform helps fertility clinics make data-driven clinical decisions, from diagnosis to treatment, to enhance live birth rates. It streamlines the patient pathway, reducing the time to treatment from three years to just 30 days through at-home testing and AI-enabled care.

NeuroVirt is a developer of innovative movement rehabilitation solutions that leverage artificial intelligence and immersive virtual reality technology. The company creates engaging rehabilitation games that can be utilized in clinical settings or at home, facilitating access to high-intensity rehabilitation doses. By integrating sensor technology, NeuroVirt's games incentivize patients to enhance their health outcomes while offering healthcare professionals accurate oversight of patient progress, both remotely and onsite. This approach not only quantifies movement rehabilitation but also aims to improve predictive recovery metrics, ultimately transforming traditional rehabilitation practices.